Open Access Research article

Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire

Patrick A Coffie123, Besigin Tonwe-Gold123, Aristophane K Tanon4, Clarisse Amani-Bosse1, Gédéon Bédikou1, Elaine J Abrams5, François Dabis23 and Didier K Ekouevi123*

Author Affiliations

1 Programme MTCT-Plus, ACONDA, BP: 1954 Abidjan 18, Abidjan, Côte d'Ivoire

2 Institut de Santé Publique, Epidémiologie et Développement (ISPED), Université Victor Segalen Bordeaux 2, 149 rue Leo Saignat, 33076, Bordeaux, France

3 Centre de Recherche INSERM U897, 149 rue Leo Saignat, 33076, Bordeaux, France

4 Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire Treichville, BP: 1954 Abidjan 18, Abidjan, Côte d'Ivoire

5 MTCT-Plus Initiative, International Center for AIDS Care and Treatment Programs (ICAP), Mailman School of Public Health, Columbia University, 722 West 168th Street, 7th floor, New York, NY, 10032, USA New-York, NY, USA

For all author emails, please log on.

BMC Infectious Diseases 2010, 10:188  doi:10.1186/1471-2334-10-188

Published: 24 June 2010

Abstract

Background

In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, data on severe adverse events (SAEs) according to CD4 cell count are limited. We estimated the incidence of SAEs according to CD4 cell count and identify their risk factors in nevirapine-treated women.

Methods

All HIV-infected women who initiated nevirapine-containing regimen in the MTCT-Plus operational program in Abidjan, Côte d'Ivoire, were eligible for this study. Laboratory and clinical (rash) SAEs were classified as grade 3 and 4. Cox models were used to identify factors associated with the occurrence of SAEs.

Results

From August 2003 to October 2006, 290 women initiated a nevirapine-containing regimen at a median CD4 cell count of 186 cells/mm3 (IQR 124-266). During a median follow-up on treatment of 25 months, the incidence of all SAEs was 19.5/100 patient-years. The 24-month probability of occurrence of hepatotoxicity or rash was not different between women with a CD4 cell count >250 cells/mm3 and women with a CD4 cell count ≤250 cells/mm3 (8.3% vs. 9.9%, Log-rank test: p = 0.75). In a multivariate proportional hazard model, neither CD4 cell count >250 cells/mm3 at treatment initiation nor initiation NVP-based regimen initiated during pregnancy were associated with the occurrence of SAEs.

Conclusion

CD4 cell count >250 cells/mm3 was not associated with a higher risk of severe hepatotoxicity and/or rash, as well as initiation of ART during pregnancy. Pharmacovogilance data as well as meta-analysis on women receiving NVP in these settings are needed for better information about NVP toxicity.